TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22183220

Group type: EXPERIMENTAL
Intervention: Porcine subintestinal submucosal graft augmentation
Number of subjects: 160

Group type: COMPARATOR
Intervention: Native tissue repair
Number of subjects: 160
Study: 21058598

Group type: EXPERIMENTAL
Intervention: Structured physical fitness program for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study: 17416085

Group type: EXPERIMENTAL
Intervention: Physical contact during venipuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no physical contact)
Number of subjects: 0
Study: 15811562

Group type: COMPARATOR
Intervention: Diet (D-group; n = 25)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Diet and exercise (DE-group; n = 30)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (C-group; n = 22)
Number of subjects: 77
Study: 12472197

Group type: EXPERIMENTAL
Intervention: Serum type IV collagen levels measured by ELISA
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Serum hemoglobin A1c (HbA1c)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Twenty-four hour urinary albumin excretion rates (UAER)
Number of subjects: 36
Study: 9531874

Group type: EXPERIMENTAL
Intervention: IM triptorelin (3.75 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SC triptorelin (3.75 mg)
Number of subjects: 40
Study: 7866809

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy with absolute ethanol (group 1, n = 19)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL; group 2, n = 16)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy and EVL
Number of subjects: 35
Study: 2487529

Group type: EXPERIMENTAL
Intervention: Indapamide (IND) 2.5 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg + Amiloride 2.5 mg (HCTZ + A)
Number of subjects: 13
Study: 787788

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 868

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 868
Study: 28810466

Group type: EXPERIMENTAL
Intervention: Cuidate programme
Number of subjects: 626

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 626
Study: 26989888

Group type: EXPERIMENTAL
Intervention: 100 μg PEX168
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 200 μg PEX168
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 26296497

Group type: EXPERIMENTAL
Intervention: A/H5N2 live attenuated influenza vaccine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22917442

Group type: EXPERIMENTAL
Intervention: Optibond FL (OF), three‐step total‐etch
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Optibond Solo Plus (OS), two‐step total‐etch
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Optibond All‐In‐One (OA), one step self‐etch
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study: 21702674

Group type: EXPERIMENTAL
Intervention: Opalescence PF
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treswhite Supreme
Number of subjects: 100
Study: 19929597

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin (E/S) combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: rosuvastatin
Number of subjects: 0
Study: 17016527

Group type: EXPERIMENTAL
Intervention: Standardized IOP treatment protocol (ranging from topical monotherapy to filtration surgery)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Standardized IOP treatment protocol
Number of subjects: 258
Study: 12633984

Group type: EXPERIMENTAL
Intervention: ALA application for 3 hours
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ALA application for 2 hours
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ALA application for 4 hours
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ALA application for 3 hours and 4 hours
Number of subjects: 40
Study: 10701278

Group type: EXPERIMENTAL
Intervention: 30 degrees semi‐Fowler position
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: prone position
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 30 degrees laterally inclined position
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 90 degrees side lying position
Number of subjects: 62

Group type: COMPARATOR
Intervention: Tempur polyethylene‐urethane mattress
Number of subjects: 62
Study: 9062507

Group type: COMPARATOR
Intervention: Regular insulin (0.15 U/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lispro insulin (0.15 U/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lispro insulin (0.1 U/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1:1 mixture of Lispro and Regular insulins (0.15 U/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ultralente insulin (0.2 U/kg)
Number of subjects: 12
Study: 1288510

Group type: EXPERIMENTAL
Intervention: Trospium chloride 0.2 mg i.v.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Trospium chloride 0.5 mg i.v.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Trospium chloride 1.0 mg i.v.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Trospium chloride 1.5 mg i.v.
Number of subjects: 6

Group type: COMPARATOR
Intervention: n-butylscopolamine bromide 20 mg i.v.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2949686

Group type: EXPERIMENTAL
Intervention: EXS Dacron
Number of subjects: 90

Group type: COMPARATOR
Intervention: Human umbilical vein grafts (HUV)
Number of subjects: 90
Study: 30739935

Group type: COMPARATOR
Intervention: Bupivacaine 2 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg/kg with Clonidine 1 µg/kg
Number of subjects: 64
Study: 29435955

Group type: EXPERIMENTAL
Intervention: Neuromuscular manual therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Back massage therapy
Number of subjects: 20
Study: 26760111

Group type: EXPERIMENTAL
Intervention: SCIT 0.25 SPT units
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: SCIT 0.5 SPT units
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: SCIT 1.0 SPT units
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: SCIT 2.0 SPT units
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: SCIT 4.0 SPT units
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 24382170

Group type: EXPERIMENTAL
Intervention: CAF + CTG
Number of subjects: 50

Group type: COMPARATOR
Intervention: CAF
Number of subjects: 50
Study: 21780981

Group type: EXPERIMENTAL
Intervention: Positive Choices Intervention (PCI)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Standard Intervention (SI)
Number of subjects: 347
Study: 20212197

Group type: EXPERIMENTAL
Intervention: 700 microg dexamethasone DDS
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 350 microg dexamethasone DDS
Number of subjects: 171

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Dexamethasone DDS (both dosages)
Number of subjects: 171
Study: 17713400

Group type: EXPERIMENTAL
Intervention: Tight glucose control by intensive insulin therapy
Number of subjects: 0
Study: 16218925

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate solution
Number of subjects: 5

Group type: COMPARATOR
Intervention: Flavoured water (placebo)
Number of subjects: 5
Study: 11994594

Group type: EXPERIMENTAL
Intervention: Irradiated patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonirradiated patients
Number of subjects: 60
Study: 10470753

Group type: EXPERIMENTAL
Intervention: Liposomal prostaglandin E1
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Liposomal prostaglandin E1 (with at least 85% of full dose)
Number of subjects: 350
Study: 8682090

Group type: EXPERIMENTAL
Intervention: Hyperimmunoglobulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon alpha
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunosuppression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2090189

Group type: EXPERIMENTAL
Intervention: Elective cholecystectomy and operative cholangiogram (group A)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Cholecystectomy without operative cholangiogram (group B)
Number of subjects: 127
Study: 287554

Group type: EXPERIMENTAL
Intervention: Adjuvant high-dose methotrexate and aggressive resection of pulmonary metastases
Number of subjects: 39

Group type: COMPARATOR
Intervention: Historical control patients
Number of subjects: 39
Study: 30907987

Group type: EXPERIMENTAL
Intervention: Levothyroxine 50 μg once daily
Number of subjects: 952

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 952
Study: 28184996

Group type: EXPERIMENTAL
Intervention: Mobile-bearing total knee arthroplasty (MB TKA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Fixed-bearing total knee arthroplasty (FB TKA)
Number of subjects: 41
Study: 26228425

Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 21
Study: 23529786

Group type: EXPERIMENTAL
Intervention: 20 mg oral tablet of bilastine
Number of subjects: 12

Group type: COMPARATOR
Intervention: 10 mg intravenous formulation of bilastine
Number of subjects: 12
Study: 20512334

Group type: EXPERIMENTAL
Intervention: FDR GEM plus PACL
Number of subjects: 42
Study: 18987965

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation
Number of subjects: 40
Study: 16759924

Group type: EXPERIMENTAL
Intervention: Endometriosis patients (n=6)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Endometriosis patients (n=15)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Controls (n=5)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Controls (n=15)
Number of subjects: 21
Study: 14657226

Group type: EXPERIMENTAL
Intervention: Consolidation radiation (RT)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Chemotherapy alone (CTh)
Number of subjects: 251
Study: 11136909

Group type: EXPERIMENTAL
Intervention: 3000 U anti-factor Xa certoparin once daily
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 3000 U anti-factor Xa certoparin twice daily
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 5000 U anti-factor Xa certoparin twice daily
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 8000 U anti-factor Xa certoparin twice daily
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Treatment group 1
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Treatment group 2
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Treatment group 3
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Treatment group 4
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: During certoparin treatment
Number of subjects: 404
Study: 9209644

Group type: EXPERIMENTAL
Intervention: Fluorescent in situ hybridization (FISH)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Reverse-transcriptase PCR (RT-PCR)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Immunostaining for p80 protein
Number of subjects: 25

Group type: COMPARATOR
Intervention: FISH
Number of subjects: 25
Study: 7711463

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3312399

Group type: EXPERIMENTAL
Intervention: Thiothixene (60 mg daily)
Number of subjects: 42
Study: 31088732

Group type: EXPERIMENTAL
Intervention: active cTBS + facilitating cues
Number of subjects: 107

Group type: COMPARATOR
Intervention: sham cTBS + facilitating cues
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: active cTBS + inhibiting cues
Number of subjects: 107

Group type: COMPARATOR
Intervention: sham cTBS + inhibiting cues
Number of subjects: 107
Study: 30044704

Group type: EXPERIMENTAL
Intervention: Dignity therapy
Number of subjects: 0
Study: 26553236

Group type: EXPERIMENTAL
Intervention: Higher systolic blood pressure targets (130-149 mm Hg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower systolic blood pressure targets (<130 mm Hg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher diastolic blood pressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower diastolic blood pressure
Number of subjects: 0
Study: 24728212

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin plus 2 g calcium daily until delivery
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 22852799

Group type: EXPERIMENTAL
Intervention: Intervention group (271 children)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control group (272 children)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Shadow control group (estimated 394 children)
Number of subjects: 271
Study: 20173085

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg every 12 hours for 10 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17658393

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg and Valsartan 320 mg
Number of subjects: 1797

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 1797

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 1797

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1797
Study: 15821705

Group type: EXPERIMENTAL
Intervention: Perindopril alone (n=53)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Perindopril + Amiodarone (n=53)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Perindopril + Metoprolol (n=32)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Perindopril + Bisoprolol (n=32)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Perindopril + Carvedilol (n=32)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Perindopril + Atenolol (n=32)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Perindopril + Amiodarone + Carvedilol (n=53)
Number of subjects: 287
Study: 12825762

Group type: EXPERIMENTAL
Intervention: Obese children (energy intake)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Obese children (energy expenditure)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Non-obese children (physical activity level)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Obese children (energy balance)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Energy balance (risk factor)
Number of subjects: 440
Study: 10088735

Group type: EXPERIMENTAL
Intervention: Phakic anterior chamber intraocular lenses implantation
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Retinal detachment repair
Number of subjects: 166
Study: 7589032

Group type: EXPERIMENTAL
Intervention: 0.075 mg gestodene and 0.03 mg ethinylestradiol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.125 mg levonorgestrel and 0.03 mg ethinylestradiol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both contraceptive formulations
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Post-treatment (1 month after last intake)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both preparations
Number of subjects: 20

Group type: COMPARATOR
Intervention: Caffeine and ethinylestradiol
Number of subjects: 20
Study: 2107743

Group type: EXPERIMENTAL
Intervention: Hydralazine 50 mg bid
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydralazine 100 mg bid
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg bid
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 293505

Group type: EXPERIMENTAL
Intervention: Randomized suppressive therapy trial
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Thyroid operations
Number of subjects: 735
Study: 30239017

Group type: EXPERIMENTAL
Intervention: Ultrasound evaluation of morphologic changes (Lateral Cartilage Clarity, Medial Cartilage Clarity, Medial Cartilage Thickness, Medial Meniscus Protrusion, Osteophytes at medial femoral margin)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Ultrasound evaluation including age and sex
Number of subjects: 113
Study: 29091238

Group type: EXPERIMENTAL
Intervention: Clinical scholar approach enhanced by systems engineering
Number of subjects: 0
Study: 26547351

Group type: EXPERIMENTAL
Intervention: Bicyclol combined with ganciclovir (bicyclol 3 mg/kg, twice daily; ganciclovir 5 mg/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ganciclovir alone (5 mg/kg)
Number of subjects: 70
Study: 25618967

Group type: EXPERIMENTAL
Intervention: Chishaodanpi decoction (CSDPD), 100 mL twice a day for 8 weeks, in addition to control treatment.
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group treatment with potassium magnesium aspartate, diammonium glycyrrhizinate, glucurolactone, vitamin C, and lamivudine, once a day for 8 weeks.
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both groups received treatment for 8 weeks.
Number of subjects: 107
Study: 22176384

Group type: COMPARATOR
Intervention: Probiotics (exact dosage and duration not specified)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Two-week data collection
Number of subjects: 126
Study: 19998861

Group type: EXPERIMENTAL
Intervention: Compensation contingent on number of complete (> or = 10 hours) days of data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily journal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three phone calls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 17385117

Group type: EXPERIMENTAL
Intervention: SLT with SLT-System I (Glautec AG, ARC, EC)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: SLT with SLT-System II (Lumenis, Palo Alto, CA)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT) with Argus (Aesculap Meditec, EC)
Number of subjects: 284
Study: 14748891

Group type: EXPERIMENTAL
Intervention: Levothyroxine (L‐T4) treatment for 1 year
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 11302598

Group type: EXPERIMENTAL
Intervention: Morphine-infused silver sulfadiazine cream
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 9631981

Group type: EXPERIMENTAL
Intervention: Maximally tolerated oral therapy (diuretics, vasodilators, and digitalis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy at standard doses
Number of subjects: 0
Study: 7992670

Group type: EXPERIMENTAL
Intervention: ad lib smoking
Number of subjects: 13

Group type: COMPARATOR
Intervention: overnight abstinence
Number of subjects: 13
Study: 2733125

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 5312248

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (100 mg daily)
Number of subjects: 8169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8169

Group type: COMPARATOR
Intervention: Non-medicated internal control
Number of subjects: 8169
Study: 31444598

Group type: EXPERIMENTAL
Intervention: Radiomics machine-learning signature
Number of subjects: 178

Group type: COMPARATOR
Intervention: Biopsy
Number of subjects: 178

Group type: COMPARATOR
Intervention: LI-RADS scores
Number of subjects: 178
Study: 31074844

Group type: EXPERIMENTAL
Intervention: VA hospital-CLC transitions
Number of subjects: 388339

Group type: EXPERIMENTAL
Intervention: Non-VA hospital to VA-contracted nursing home transitions
Number of subjects: 388339

Group type: COMPARATOR
Intervention: VA hospitals
Number of subjects: 388339

Group type: COMPARATOR
Intervention: Non-VA hospital to VA-contracted nursing homes
Number of subjects: 388339

Group type: COMPARATOR
Intervention: Non-VA hospital to CLC
Number of subjects: 388339
Study: 28423969

Group type: EXPERIMENTAL
Intervention: PULSE Program intervention (self-administered lifestyle intervention focused on weight loss, diet, and exercise)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: PULSE Program intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 101
Study: 26697487

Group type: EXPERIMENTAL
Intervention: Pharmaceutical Intervention (PI) - information booklets, 30 min face-to-face medication education and psychological counseling by clinical pharmacists, 2 sessions per week for 2 months
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group - conventional treatment only
Number of subjects: 149
Study: 24152861

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: SAVR
Number of subjects: 630
Study: 21696849

Group type: EXPERIMENTAL
Intervention: Nutrilarm(®) capsules (omega-3 and omega-6), twice a day for 6 months
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Nutrilarm(®) capsules
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 18448309

Group type: EXPERIMENTAL
Intervention: Groton Maze Learning Test (GMLT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CogState computerized cognitive test battery (CGS)
Number of subjects: 0
Study: 16254268

Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol (15 microg kg(‐1) h(‐1)) for 7 days
Number of subjects: 40
Study: 12968981

Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (Daunoxome) administered as a 1‐ to 2.5 h infusion with doses ranging from 30 to 60 mg m(‐2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Liposomal daunorubicin (Daunoxome)
Number of subjects: 24
Study: 11090729

Group type: EXPERIMENTAL
Intervention: 1 microg/kg epidural neostigmine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 500 microg intraarticular neostigmine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 1 microg/kg intraarticular neostigmine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (CG) - normal saline
Number of subjects: 58
Study: 8941095

Group type: EXPERIMENTAL
Intervention: High dietary fiber intake (median, 34.8 g/d)
Number of subjects: 21930

Group type: COMPARATOR
Intervention: Low dietary fiber intake (median, 16.1 g/d)
Number of subjects: 21930

Group type: EXPERIMENTAL
Intervention: Water-soluble fiber
Number of subjects: 21930

Group type: EXPERIMENTAL
Intervention: Cereal fiber
Number of subjects: 21930
Study: 1417428

Group type: EXPERIMENTAL
Intervention: Active imipramine hydrochloride treatment maintained at an average dose of 200 mg
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128